Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.44 |
| ▸ | CPT1A | P50416 | 1/20 | 0.44 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290366 | 0.91 | CPT2 (0.48) | CPT2CPT1ACPT1BDRD2ADRA1D | |
| SCHEMBL8061914 | 0.91 | NR1H2 (0.39) | CPT2CPT1ACPT1BDRD2CTSL | |
| SCHEMBL8067031 | 0.88 | CPT2 (0.47) | CPT2CPT1ACPT1BDRD2ADRA1D | |
| SCHEMBL3946155 | 0.84 | CTSL (0.52) | CPT2CPT1ACPT1BDRD2ADRA1D | |
| SCHEMBL13663720 | 0.84 | CTSL (0.52) | CPT2CPT1ACPT1BDRD2ADRA1D | |
| SCHEMBL4215206 | 0.84 | CTSL (0.55) | CPT2CPT1ACPT1BDRD2ADRA1D | |
| SCHEMBL13661952 | 0.84 | CPT2 (0.45) | CPT2CPT1ACPT1BDRD2ADRA1D | |
| SCHEMBL8063010 | 0.82 | NR1H2 (0.41) | CPT2CPT1ACPT1BDRD2CTSL | |
| SCHEMBL13663721 | 0.82 | CPT2 (0.42) | CPT2CPT1ACPT1BDRD2ADRA1D | |
| SCHEMBL8047069 | 0.82 | CPT2 (0.46) | CPT2CPT1ACPT1BDRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | CPT2 3009/4885CPT1A 3354/4885CPT1B 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.